| Literature DB >> 29786691 |
Sujing Jiang1, Rongjie Zhao2, Yiran Li2, Xufeng Han3, Zhen Liu2, Weiting Ge4, Ying Dong5, Weidong Han6.
Abstract
As primary duodenal adenocarcinoma is rare, the prognostic factors of this disease remain insufficiently explored, especially in China. We identified postoperative duodenal adenocarcinoma patients at a Chinese double-center (from 2006 to 2016) or who were registered with the Surveillance, Epidemiology, and End Results (SEER) database (from 2004 to 2014). Clinicopathological features and significant prognostic factors for cancer-specific survival (CSS) were reviewed and analyzed by using univariate and multivariate Cox proportional hazards regression. Then, a nomogram predicting CSS was constructed based on the SEER database and validated externally by using the separate Chinese cohort. Totally, 137 patients from the Chinese double-center and 698 patients from the SEER database were included for analysis. The multivariate analyses showed that age, tumor grade and TNM stage were independent prognostic factors. The nomogram constructed using these factors showed a clear prognostic superiority to the AJCC-TNM classification, 7th ed. (C-index: SEER cohort, 0.693 vs 0.625, P < 0.001; Chinese cohort, 0.677 vs 0.659, P < 0.001, respectively). In summary, the valuable prognostic factors in patients with duodenal adenocarcinoma were age, tumor grade and TNM stage. This study developed a nomogram that can precisely predict the CSS for postoperative duodenal adenocarcinoma patients.Entities:
Mesh:
Year: 2018 PMID: 29786691 PMCID: PMC5962558 DOI: 10.1038/s41598-018-26145-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinicopathological features of the Chinese and SEER cohort with postoperative duodenal adenocarcinoma.
| Variable | Chinese cohort | SEER cohort |
|---|---|---|
| Sex | ||
| Men | 84 (61.3%) | 352 (50.4%) |
| Female | 53 (38.7%) | 346 (49.6%) |
| Age | ||
| ≤58 | 55 (40.1%) | 238 (34.1%) |
| 59–75 | 58 (42.3%) | 315 (45.1%) |
| >75 | 24 (17.8%) | 145 (20.8%) |
| Race | ||
| Caucasians | — | 532 (76.2%) |
| African Americans | — | 112 (16.0%) |
| Others | — | 54 (7.7%) |
| Tumor grade | ||
| Well | 41 (29.9%) | 55 (7.9%) |
| Moderate | 68 (49.6%) | 365 (52.3%) |
| Poor | 28 (20.4%) | 264 (37.8%) |
| Undifferentiated | 14 (2.0%) | |
| Size | ||
| ≤2 cm | 59 (43.1%) | 86 (12.3%) |
| 2–4 cm | 54 (39.4%) | 308 (44.1%) |
| >4 cm | 24 (17.5%) | 304 (43.65) |
| T stage | ||
| T1 | 11 (8.9%) | 33 (4.7%) |
| T2 | 35 (25.5%) | 58 (8.3%) |
| T3 | 32 (23.4%) | 254 (36.4%) |
| T4 | 59 (43.1%) | 353 (50.6%) |
| N stage | ||
| N0 | 95 (69.3%) | 269 (38.5%) |
| N1 | 32 (23.4%) | 255 (36.5%) |
| N2 | 10 (7.3%) | 174 (24.9%) |
| M stage | ||
| M0 | 121 (88.3%) | 650 (93.1%) |
| M1 | 16 (11.7%) | 48 (6.9%) |
| Stage | ||
| Stage I | 36 (26.3%) | 62 (8.9%) |
| Stage II | 49 (35.8%) | 201 (28.8%) |
| Stage III | 36 (26.3%) | 387 (55.4%) |
| Stage IV | 16 (11.7%) | 48 (6.9%) |
| Vascular invasion | ||
| No | 112 (81.8%) | — |
| Yes | 25 (18.2%) | — |
| Perineural invasion | ||
| No | 113 (82.5%) | — |
| Yes | 24 (17.5%) | — |
Incidence of initial symptoms and laboratory tests in Chinese cohort with postoperative duodenal adenocarcinoma.
| Variable | Patient demographics (%) |
|---|---|
| Symptom at diagnosis | |
| Alimentray symptoms | 90 (65.7%) |
| Abdominal pain | 53 (38.7%) |
| Nausea and vomiting | 25 (18.2%) |
| Gastrointestional bleeding | 12 (8.8%) |
| Jaundice | 32 (23.4%) |
| Itching | 11 (8.0%) |
| Asymoptomatic | 8 (5.8%) |
| Others* | 34 (24.8%) |
| CEA | |
| Normal | 70 (67.2%) |
| High | 18 (13.1%) |
| Inconclusion | 27 (19.7%) |
| CA19–9 | |
| Normal | 70 (51.1%) |
| High | 40 (29.2%) |
| Inconclusion | 27 (19.7%) |
Abbreviations: CEA, carcinoembryonic antigen; CA19–9, carbohydrate antigen 19–9; Others* included weight loss, fatigue and fever.
Univariate analysis of patients with postoperative duodenal adenocarcinoma in Chinese and SEER cohort.
| Variable | Chinese cohort | SEER cohort | ||
|---|---|---|---|---|
| Hazard Ratio (95%CI) |
| Hazard Ratio (95%CI) |
| |
| Race | 0.477 | |||
| Caucasians | — | — | ||
| African Americans | — | — | 0.944 (0.690–1.290) | 0.716 |
| Others | — | — | 0.748 (0.468–1.207) | 0.234 |
| Sex | 0.299 | 0.119 | ||
| Male | — | — | — | — |
| Female | 0.733 (0.407–1.320) | 0.301 | 0.837 (0.669–1.047) | 0.120 |
| Age | 0.127 | <0.001 | ||
| ≤58 | — | — | — | — |
| 59–75 | 1.098 (0.571–2.112) | 0.779 | 1.599 (1.216–2.102) | 0.001 |
| >75 | 2.013 (0.985–4.115) | 0.550 | 2.741 (2.020–3.720) | <0.001 |
| Tumor grade | 0.110 | 0.003 | ||
| Well | — | — | — | |
| Moderate | 1.309 (0.898–1.907) | 0.162 | 0.853 (0.676–1.077) | 0.181 |
| Poor | 1.223 (0.773–1.936) | 0.389 | 1.145 (0.903–1.451) | 0.264 |
| Undifferentiated | — | — | 1.728 (1.066–2.803) | 0.027 |
| Size | 0.275 | 0.001 | ||
| ≤2 cm | — | — | — | — |
| 2–4 cm | 0.683 (0.372–1.253) | 0.218 | 1.667 (1.145–2.426) | 0.008 |
| >4 cm | 0.549 (0.225–1.339) | 0.187 | 1.133 (0.769–1.669) | 0.527 |
| T stage | 0.470 | <0.001 | ||
| T1 | — | — | — | — |
| T2 | 0.769 (0.257–2.302) | 0.639 | 1.947 (0.694–5.464) | 0.205 |
| T3 | 1.273 (0.452–3.586) | 0.648 | 3.488 (1.420–8.567) | 0.006 |
| T4 | 1.397 (0.525–3.721) | 0.503 | 5.407 (2.223–13.155) | <0.001 |
| N stage | <0.001 | <0.001 | ||
| N0 | — | — | — | — |
| N1 | 1.392 (0.708–2.734) | 0.337 | 1.676 (1.273–2.206) | <0.001 |
| N2 | 6.306 (2.776–14.321) | <0.001 | 2.339 (1.744–3.137) | <0.001 |
| M stage | 0.007 | <0.001 | ||
| M0 | — | — | — | — |
| M1 | 2.769 (1.279–5.985) | 0.01 | 2.163 (1.419–3.138) | <0.001 |
| Stage | 0.003 | <0.001 | ||
| Stage I | — | — | ||
| Stage II | 0.941 (0.414–2.135) | 0.884 | 2.464 (1.306–4.648) | 0.005 |
| Stage III | 2.268 (1.065–4.830) | 0.034 | 3.699 (2.014–6.795) | <0.001 |
| Stage IV | 3.649 (1.439–9.249) | 0.006 | 6.488 (3.257–12.925) | <0.001 |
| Vascular invasion | 0.637 | |||
| No | — | — | — | — |
| Yes | 1.201 (0.561–2.575) | 0.637 | — | — |
| Perineural invasion | 0.998 | |||
| No | — | — | — | — |
| Yes | 0.999 (0.423–2.360) | 0.998 | — | — |
Multivariate analysis of patients with postoperative duodenal adenocarcinoma in Chinese and SEER cohort.
| Variable | Chinese cohort | SEER cohort | ||
|---|---|---|---|---|
| Hazard Ratio (95%CI) |
| Hazard Ratio (95%CI) |
| |
| Race | 0.293 | |||
| Caucasians | — | — | — | — |
| African Americans | — | — | 1.227 (0.888–1.696) | 0.215 |
| Others | — | — | 0.817 (0.503–1.329) | 0.416 |
| Sex | 0.299 | |||
| Male | — | — | — | — |
| Female | 0.733 (0.407–1.320) | 0.301 | 0.889 (0.706–1.118) | 0.313 |
| Age | 0.127 | <0.001 | ||
| ≤58 | — | — | — | — |
| 59–75 | 1.098 (0.571–2.112) | 0.779 | 1.710 (1.296–2.257) | <0.001 |
| ≥75 | 2.013 (0.985–4.115) | 0.55 | 3.101 (2.275–4.227) | <0.001 |
| Tumor grade | 0.110 | 0.040 | ||
| Well | — | — | — | — |
| Moderate | 1.309 (0.898–1.907) | 0.162 | 1.063 (0.634–1.718) | 0.817 |
| Poor | 1.223 (0.773–1.936) | 0.389 | 1.282 (0.759–2.163) | 0.353 |
| Undifferentiation | — | — | 2.488 (1.125–5.500) | 0.024 |
| Size | 0.275 | 0.053 | ||
| ≤2 cm | — | — | — | — |
| 2–4 cm | 0.683 (0.372–1.253) | 0.218 | 1.018 (0.730–1.603) | 0.697 |
| >4 cm | 0.549 (0.225–1.339) | 0.187 | 0.802 (0.533–1.206) | 0.289 |
| T stage | 0.470 | <0.001 | ||
| T1 | — | — | — | — |
| T2 | 0.769 (0.257–2.302) | 0.639 | 2.143 (0.741–6.197) | 0.159 |
| T3 | 1.273 (0.452–3.586) | 0.648 | 3.451 (1.332–8.941) | 0.011 |
| T4 | 1.397 (0.525–3.721) | 0.503 | 4.803 (1.876–12.297) | 0.001 |
| N stage | <0.001 | 0.001 | ||
| N0 | — | — | — | — |
| N1 | 1.392 (0.708–2.734) | 0.337 | 1.378 (1.033–1.837) | 0.029 |
| N2 | 6.306 (2.776–14.321) | <0.001 | 1.834 (1.340–2.510) | <0.001 |
| M stage | 0.007 | <0.001 | ||
| M0 | — | — | — | — |
| M1 | 2.769 (1.279–5.985) | 0.01 | 2.191 (1.490–3.220) | <0.001 |
Figure 1Kaplan-Meier curves of CSS for patients with postoperative duodenal adenocarcinoma in the Chinese cohort (a) and SEER cohort (b) by risk group stratification within each pN stage.
Demographic and clinicopathologic variables of postoperative duodenal adenocarcinoma patients with or without LN metastasis in Chinese and SEER cohort.
| Variable | Chinese cohort | SEER cohort | ||
|---|---|---|---|---|
| LN negative | LN positive | LN negative | LN positive | |
| Sex | ||||
| Men | 52 (61.9%) | 20 (54.1%) | 126 (47.5%) | 203 (52.7%) |
| Female | 32 (38.1%) | 17 (45.9%) | 139 (52.5%) | 182 (47.3%) |
| Age | ||||
| ≤58 | 36 (42.9%) | 14 (37.8%) | 84 (31.7%) | 132 (34.3%) |
| 59–75 | 34 (40.5%) | 17 (45.9%) | 120 (45.3%) | 177 (46.0%) |
| >75 | 14 (16.7%) | 6 (16.2%) | 61 (23.0%) | 76 (19.7%) |
| Tumor grade | ||||
| Well | 39 (46.4%) | 19 (51.4%) | 35 (13.2%) | 18 (4.7%) |
| Moderate | 16 (19.0%) | 10 (27.0%) | 139 (52.5%) | 204 (53.0%) |
| Poor | 29 (34.5%) | 8 (21.6%) | 85 (32.1%) | 155 (40.3%) |
| Undifferentiated | — | — | 6 (2.3%) | 8 (2.1%) |
| Size | ||||
| ≤2 cm | 81 (96.4%) | 34 (91.9%) | 50 (18.9%) | 32 (8.3%) |
| 2–4 cm | 3 (3.6%) | 3 (8.1%) | 100 (37.7%) | 179 (46.5%) |
| >4 cm | — | — | 115 (43.4%) | 174 (45.2%) |
| T stage | ||||
| T1 | 10 (11.9%) | 1 (2.7%) | 26 (9.8%) | 5 (1.3%) |
| T2 | 30 (35.7%) | 4 (10.8%) | 36 (13.6%) | 22 (5.7%) |
| T3 | 20 (23.8%) | 9 (24.3%) | 109 (41.1%) | 125 (32.5%) |
| T4 | 24 (28.6%) | 23 (62.6%) | 94 (35.5%) | 233 (60.5%) |
Multivariable logistic regression for predictors of LN metastasis of postoperative duodenal adenocarcinoma patients in Chinese and SEER cohort.
| Variable | Chinese cohort | SEER cohort | ||
|---|---|---|---|---|
| Hazard Ratio (95%CI) |
| Hazard Ratio (95%CI) |
| |
| Tumor grade | 0.769 | 0.044 | ||
| Well | — | — | — | — |
| Moderate | 1.221 (0.413–3.610) | 0.719 | 2.326 (1.212–4.466) | 0.011 |
| Poor | 1.574 (0.459–5.397) | 0.470 | 2.640 (1.347–5.174) | 0.005 |
| Undifferentiated | — | — | 2.009 (0.573–7.042) | 0.276 |
| T stage | 0.004 | <0.001 | ||
| T1 | — | — | — | — |
| T2 | 1.333 (0.133–13.368) | 0.180 | 2.601 (0.856–7.900) | 0.092 |
| T3 | 4.500 (0.498–40.654) | 0.038 | 4.652 (1.693–12.781) | 0.003 |
| T4 | 9.583 (1.135–80.942) | 0.028 | 10.199 (3.736–27.844) | <0.001 |
Figure 2Nomogram predicting the 3-year and 5-year CSS for postoperative duodenal adenocarcinoma patients.
Figure 3The calibration curves for predicting patient CSS at (A) 3-year and (B) 5-year in the training cohort, and at (C) 3-year and (D) 5-year in the external validation cohort. Nomogram-predicted survival is plotted on the x-axis, and the actual survival is plotted on the y-axis.